Site content: Global

Press Release

Menarini Silicon Biosystems announces new DEPArray™ PLUS application to identify mutations in FFPE tissue samples with low tumor cellularity

Tissue biopsies with tumor cell contents that are too low for conventional testing methods can now be rescued due to the ability of MSB’s DEPArray technology* to successfully...

Menarini Silicon Biosystems Develops New Assay Workflow for Circulating Multiple Myeloma Cells

Technology to Be Introduced at the Molecular Medicine Tri-Conference May Offer Alternative to Invasive Bone Marrow Biopsy for Monitoring Disease Progression Bologna, Italy and...

Top International Experts Gather to Understand the Many Faces of Cancer

Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington   WASHINGTON, D.C., May 11, 2017 – Cancer experts from around the world will...

Menarini-Silicon Biosystems and Swift Biosciences Announce Collaboration to Offer Customized NGS Technologies for Tumor Cell Analysis

Products Optimized for Targeted Resequencing and Exome Sequencing of FFPE Cells BOLOGNA, Italy, October 25, 2016 – Menarini-Silicon Biosystems Inc., a developer and manufacturer...

Silicon Biosystems DEPArray™ technology offers a revolutionary approach to understanding complex cancer genomics in FFPE samples.

Silicon Biosystems, a Bologna (Italy) and San Diego (CA, USA) based biotech company that is part of the pharmaceutical Menarini Group, presented recent findings obtained with its...